Hyperliquid Strategies completes business combination with Sonnet BioTherapeutics Dec 2, 2025 04:31PM
Sonnet BioTherapeutics stockholders approve business combination Dec 2, 2025 09:17AM
Sonnet BioTherapeutics adds higher dose cohort in ovarian cancer trial Aug 4, 2025 08:40AM
Sonnet BioTherapeutics agrees to $888 million crypto treasury deal Jul 14, 2025 06:00AM
Sonnet's (SONN) SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Apr 4, 2025 09:01AM


Apr 1, 2025 07:30AM Sonnet BioTherapeutics (SONN) Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
Mar 26, 2025 09:05AM Sonnet BioTherapeutics (SONN) Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin
Mar 19, 2025 08:50AM Sonnet BioTherapeutics (SONN) Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
Feb 19, 2025 08:37AM Sonnet BioTherapeutics (SONN) Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Can
Feb 13, 2025 08:30AM Sonnet BioTherapeutics (SONN) Appoints Stephen McAndrew as Chief Business Officer
Jan 28, 2025 09:05AM Sonnet BioTherapeutics (SONN) Issues EU Patent for FHAB Platform Technology
Jan 22, 2025 04:19PM Sonnet BioTherapeutics (SONN) Files for 2M Share Offering by Selling Stockholders
Jan 21, 2025 09:05AM Sonnet BioTherapeutics (SONN) Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
Dec 9, 2024 03:43PM Sonnet BioTherapeutics (SONN) Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Dec 9, 2024 08:45AM Sonnet BioTherapeutics (SONN) Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
Dec 4, 2024 09:20AM Sonnet BioTherapeutics (SONN) Announces Publication Detailing the Discovery and Development of SON-1010
Nov 6, 2024 01:20PM Sonnet BioTherapeutics (SONN) Prices 1.11M Share Offering at $4.50/sh
Nov 6, 2024 09:25AM Sonnet BioTherapeutics (SONN) Files for 1.1M Share and Warrant Offering
Nov 6, 2024 08:32AM Sonnet BioTherapeutics (SONN) Issues US Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Oct 28, 2024 09:07AM Sonnet BioTherapeutics (SONN) Files for Share and Warrant Offering
Oct 17, 2024 08:45AM Sonnet BioTherapeutics (SONN) Regains Nasdaq Compliance
Oct 9, 2024 08:45AM Sonnet BioTherapeutics (SONN) Enters Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080
Oct 4, 2024 08:31AM Sonnet BioTherapeutics (SONN) to Receive Non-Dilutive Funding Through NJ Tax Certificate Transfer and Australia R&D Tax Incentive Programs
Sep 30, 2024 09:00AM Sonnet BioTherapeutics (SONN) Launches CEO Corner Platform
Sep 25, 2024 08:30AM Sonnet BioTherapeutics (SONN) Announces 1:* Reverse Share Split
Aug 19, 2024 08:45AM Sonnet BioTherapeutics (SONN) Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment
Jul 24, 2024 08:31AM Sonnet BioTherapeutics (SONN) Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080
Jun 20, 2024 08:37AM Sonnet BioTherapeutics (SONN) Receives $3.4M From Warrants Exercise